Our previous data suggested an association between high tissue levels of NICD and poorer response to anti-vascular endothelial growth factor (VEGF) bevacizumab as first-line therapy in metastatic colorectal cancer (CRC) patients, but not to chemotherapy alone (11). The gene discussed is VEGFA; the disease is metastatic colorectal cancer.